2019
Trim the fat: the role of omega-3 fatty acids in psychopharmacology
Nasir M, Bloch MH. Trim the fat: the role of omega-3 fatty acids in psychopharmacology. Therapeutic Advances In Psychopharmacology 2019, 9: 2045125319869791. PMID: 31489174, PMCID: PMC6713969, DOI: 10.1177/2045125319869791.Peer-Reviewed Original ResearchPost-traumatic stress disorderDepressive disorderAmerican Psychiatric AssociationFindings of RCTsRecent negative studiesSide effect profileFatty acid supplementationFatty acidsRandomized-controlled trialEvidence of efficacySubstantial methodological shortcomingsEvidence-based treatmentsImpulse control disordersIncomplete blindingHeterogeneous sample populationsBipolar maniaTreatment guidelinesCurrent guidelinesCardiovascular diseaseAcid supplementationNegative studiesPatient complianceUnipolar depressionIneffective treatmentPsychotic disorders
2015
Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch MH, Storch EA. Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 251-262. PMID: 25791142, PMCID: PMC4460245, DOI: 10.1016/j.jaac.2015.01.011.Peer-Reviewed Original ResearchConceptsTreatment-refractory obsessive-compulsive disorderPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitorsObsessive-compulsive disorderCognitive behavioral therapyTreatment-Refractory ObsessivePharmacological treatment optionsSide effect profileSerotonin reuptake inhibitorsTreatment of adultsGlutamate-modulating agentsLittle evidence-based dataEvidence of efficacyEvidence-based dataPediatric OCD patientsOCD symptomsAntipsychotic augmentationSSRI dosagesPediatric patientsReuptake inhibitorsEffect profilePediatric populationTreatment optionsPractice guidelinesEffective treatment
2014
Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Ferracioli-Oda E, Qawasmi A, Bloch M. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. FOCUS The Journal Of Lifelong Learning In Psychiatry 2014, 12: 73-79. DOI: 10.1176/appi.focus.12.1.73.Peer-Reviewed Original ResearchPrimary sleep disordersTotal sleep timeOverall sleep qualityEffect of melatoninSleep disordersSleep qualitySleep latencySleep timeBenign side effect profilePlacebo-controlled trialSide effect profileEfficacy of melatoninTreatment of insomniaSleep onset latencyInfluence of doseDuration of melatoninMelatonin dosePrimary outcomeAbsolute benefitMelatonin usePharmacological treatmentSignificant efficacyNineteen studiesSleep parametersOnset latency
2013
Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLOS ONE 2013, 8: e63773. PMID: 23691095, PMCID: PMC3656905, DOI: 10.1371/journal.pone.0063773.Peer-Reviewed Original ResearchConceptsPrimary sleep disordersTotal sleep timeOverall sleep qualityEffect of melatoninSleep disordersSleep qualitySleep latencySleep timeBenign side effect profilePlacebo-controlled trialSide effect profileEfficacy of melatoninTreatment of insomniaSleep onset latencyInfluence of doseDuration of melatoninMelatonin dosePrimary outcomeAbsolute benefitMelatonin usePharmacological treatmentSignificant efficacyNineteen studiesSleep parametersOnset latency
2011
Omega-3 Fatty Acid Supplementation for the Treatment of Children With Attention-Deficit/Hyperactivity Disorder Symptomatology: Systematic Review and Meta-Analysis
Bloch MH, Qawasmi A. Omega-3 Fatty Acid Supplementation for the Treatment of Children With Attention-Deficit/Hyperactivity Disorder Symptomatology: Systematic Review and Meta-Analysis. Journal Of The American Academy Of Child & Adolescent Psychiatry 2011, 50: 991-1000. PMID: 21961774, PMCID: PMC3625948, DOI: 10.1016/j.jaac.2011.06.008.Peer-Reviewed Original ResearchConceptsFatty acid supplementationAttention-deficit/hyperactivity disorderAcid supplementationOmega-3 Fatty Acid SupplementationTreatment of ADHDRandomized placebo-controlled trialBenign side effect profilePlacebo-controlled trialSide effect profilePrimary outcome measurementAnti-inflammatory propertiesTreatment of childrenCell membrane fluidityEffect of dosingAvailable pharmacotherapiesFatty acidsModest efficacyPharmacologic interventionsHyperactivity disorder symptomatologyOutcome measurementsDopamine neurotransmissionAcid doseHigh dosesPsychopharmacologic optionsMeta-Analysis